Hepatitis
Hepatitis 25/11/2008
Management of HIV positive patients with chronic hepatitis B who are not eligible for antiretroviral therapy
There are limited data on how best to treat chronic hepatitis B patients coinfected with HIV. The issue is complicated by the fact that some agents used to treat hepatitis B and some antiretroviral drugs for HIV are active against both viruses, and using them inappropriately can lead to drug resistance.
Hepatitis 25/11/2008
Schering-Plough provides update on boceprevir
Schering-Plough provides update on boceprevir clinical development and introduces potent next-generation oral HCV protease inhibitor for treating patients with chronic hepatitis C.
Hepatitis 25/11/2008
Valeant reports encouraging end of treatment results with taribavirin at treatment week 48 in Phase IIb study
Continues to demonstrate similar efficacy to ribavirin with lower anemia.
Hepatitis 22/11/2008
Tibotec begins European enrollment for Phase 3 trial of telaprevir in HCV patients who failed prior treatment
Tibotec is managing the global trial, which is being conducted at more than 50 sites in Europe.
Hepatitis 19/11/2008
Tenofovir for patients with HIV-HBV coinfection
Given its dual activity, tenofovir has particular potential benefit for HIV/HBV coinfected individuals.
Hepatitis 19/11/2008
Outcomes of acute hepatitis C virus infection in people with HIV
People with HIV are less likely to experience spontaneous HCV clearance without treatment, and therefore are more likely to develop chronic liver disease.
Hepatitis 17/11/2008
Hepatitis C therapeutic DNA vaccine delivered by Inovio Biomedical's electroporation technology reduces viral load by up to 99.7%
Clinical data presented at annual scientific meeting of the American Association for the Study of Liver Diseases.
Hepatitis 12/11/2008
Experts call for new trials of hepatitis B drugs
Patients with hepatitis B virus infection have treatment options, but new clinical trials are needed to determine the best way to use these therapies, a panel of experts recently concluded.
Hepatitis 12/11/2008
HCV polymerase inhibitor PF-00868554 inhibits viral replication in treatment-naive patients
In a double-blind study, investigators evaluated the safety, tolerability, pharmacokinetics, and antiviral activity of PF-00868554 in 32 treatment-naive patients with genotype 1 chronic hepatitis C.
Hepatitis 12/11/2008
Investigational HCV protease inhibitor BI 201335 exhibits promising antiviral activity
Given the limited efficacy and side effects of interferon-based therapy for chronic hepatitis HCV infection, investigators have explored several small molecule agents that directly target various steps of the viral lifecycle.
Hepatitis 11/11/2008
HAART improves hepatitis B vaccine response regardless of CD4 count
An effective hepatitis B vaccine is available, and is recommended for all HIV positive individuals. But past studies indicate that it does not work as well for HIV positive people with advanced immune deficiency and low CD4 cell counts.
Hepatitis 10/11/2008
Roche, InterMune and Pharmasset announce initiation of INFORM-1
This is the first dual-combination clinical trial with oral antivirals in hepatitis C.
Hepatitis 07/11/2008
C-section won't stop hepatitis C transfer
The mode of childbirth has no affect on whether a child catches hepatitis C from their mother, a new Irish study shows.
Hepatitis 07/11/2008
Stopping treatment more hazardous for people with hep and HIV
Interrupting HIV therapy was associated with nearly three times as many non-AIDS-related deaths in people with HIV and either hepatitis B virus or hepatitis C virus than in people infected with only HIV.
Hepatitis 05/11/2008
SciClone and Sigma-Tau report Phase 3 hepatitis C trial results
The thymalfasin treatment group did not achieve statistical significance for the primary endpoint of sustained virological response.
Hepatitis 04/11/2008
Working with U.S. Department of Defense, Canopus BioPharma announces Phase II human clinical trial for innovative hepatitis C drug, CB5300
New treatment shows greater therapeutic efficacy than interferon alpha.
Hepatitis 04/11/2008
Progenics selects small-molecule hepatitis C drug candidate for clinical development
PRO 206 is an orally available viral-entry inhibitor, designed to prevent HCV from entering and infecting healthy liver cells.
Hepatitis 04/11/2008
ZymoGenetics presents positive interim Phase 1b results in hepatitis C
Significant viral load reduction and encouraging tolerability with PEG-interferon lambda.
Hepatitis 03/11/2008
New clinical data support broad profile for telaprevir in patients with genotype 1 hepatitis C virus infection
PROVE 3 data show 52% SVR12 in HCV treatment-failure patients with 24-week treatment duration.
Hepatitis 03/11/2008
New study shows that PEGASYS(R) regimen provides higher sustained virological response rates for hepatitis C patients
Higher sustained virological response rates recognized as marker of treatment success.
More...
